Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan C Buckner

Showing results (71-80 of 138) with videos related to

Pageof 14
Sort By:
International Journal of Radiation Oncology, Biology, Physics|January 26, 2005
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51Ravi D Rao, Sunil Krishnan, Tom R Fitch, et al.
International Journal of Radiation Oncology, Biology, Physics|June 21, 2005
Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective studyNadia N Laack, Paul D Brown, Robert J Ivnik, et al.
Journal of Medical Imaging (Bellingham, Wash.)|July 10, 2015
Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogressionZachary S Kelm, Panagiotis D Korfiatis, Ravi K Lingineni, et al.
Journal of Neuro-Oncology|November 8, 2005
Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patientsNicole E Marshall, Karla V Ballman, John C Michalak, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2006
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177Sunil Krishnan, Paul D Brown, Karla V Ballman, et al.
Investigational New Drugs|September 1, 2005
Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trialEvanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2011
Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51Thomas B Daniels, Paul D Brown, Sara J Felten, et al.
Journal of Neuro-Oncology|July 5, 2014
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytomaSani H Kizilbash, Caterina Giannini, Jesse S Voss, et al.
Neuro-Oncology|September 20, 2013
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trialsThierry Gorlia, Wenting Wu, Meihua Wang, et al.
Journal of Neurosurgery|November 4, 2008
Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trialEdward G Shaw, Brian Berkey, Stephen W Coons, et al.
Pageof 14

Showing results (71-80 of 138) with videos related to

Sort By:
Pageof 14
International Journal of Radiation Oncology, Biology, Physics|January 26, 2005
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51Ravi D Rao, Sunil Krishnan, Tom R Fitch, et al.
International Journal of Radiation Oncology, Biology, Physics|June 21, 2005
Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective studyNadia N Laack, Paul D Brown, Robert J Ivnik, et al.
Journal of Medical Imaging (Bellingham, Wash.)|July 10, 2015
Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogressionZachary S Kelm, Panagiotis D Korfiatis, Ravi K Lingineni, et al.
Journal of Neuro-Oncology|November 8, 2005
Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patientsNicole E Marshall, Karla V Ballman, John C Michalak, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2006
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177Sunil Krishnan, Paul D Brown, Karla V Ballman, et al.
Investigational New Drugs|September 1, 2005
Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trialEvanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2011
Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51Thomas B Daniels, Paul D Brown, Sara J Felten, et al.
Journal of Neuro-Oncology|July 5, 2014
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytomaSani H Kizilbash, Caterina Giannini, Jesse S Voss, et al.
Neuro-Oncology|September 20, 2013
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trialsThierry Gorlia, Wenting Wu, Meihua Wang, et al.
Journal of Neurosurgery|November 4, 2008
Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trialEdward G Shaw, Brian Berkey, Stephen W Coons, et al.
Pageof 14